Five-year follow-up of prostate cancer in Siriraj Hospital

Journal of the Medical Association of Thailand

Volumn 83, Issue 3, 2000, Pages 236-242

  Soontrapa, Suchai ^a   Tantiwong, Anuphan ^a   Leewansangtong, Sunai ^a   Bhanalaph, Thongchai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Carcinoma; Prostate; Prostatic Neoplasm

Indexed keywords

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; THAILAND;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THAILAND;

EID: 0034153747     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Vatanasapt V, Martin N, Sriplung H, et al. Cancer in Thailand 1988-1991. IARC Techical report No. 16, International Agency for Research on Cancer (WHO), Lyon Cedex, France, 1993: 108-9.
2. Landis SH, Murray T, Bolden S, et al. Cancer statistics. Ca Cancer J Clin 1998; 48: 6-29.
3. Whitmore WF Jr. Hormonal therapy in prostate cancer. Am J Med 1956; 21: 679-713.
4. Jewitt HJ. The present status of radical prostatectomy for stage A and B prostate cancer. Urol Clin North Am 1975; 2: 105-24.
5. Dawson-Saunder B, Trapp RG. Methods for analyzing survival data. In Dawson-Saunder B, Trapp RG. Basic & Clinical Biostatistics, 2 nd edn, Connecticut: Appleton & Lange. 1994: 188-209.
6. Huggins C, Hodes CV. Studies of prostatic cancer. 1. The effects of castrations, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of prostate. Cancer Res 1941; 1:293-307.
7. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Nation. Cancer Inst Monogr 1988; 7: 165-70.
8. Bruchoysky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82.
9. Public health statistic A.D. 1992. Central Information Center, Health Statistic Division, Bureau of Health Policy and Plan, Permanent Secretory, Office for Ministry of Public Health, Thailand, March 1994: 19.
10. Leewansangtong S, Crawford ED. Maximal androgen withdrawal for prostate cancer therapy: current status and future potential. Endocrine Related Cancer 1998; 5: 325-39.
11. Labrie F, Dupont A, Belanger A, et al. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 1983; 19: 999-1007.
12. Dijkman GA, Janknegt RA, De Reijke TM, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997; 158: 160-3.
13. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-24.
14. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9.
15. Crawford ED, Eisenberger MA, McLeod DG, et al. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate. Results of NCI intergroup study 0105 (SWOG and ECOG). J Urol 1997; 157 (4 suppl):336.